Q4 2024 Management View Moderna CEO Stéphane Bancel highlighted 2024 as a year of significant progress, with revenues reaching $3.2 billion. The company reduced operating expenses by $2.6 billion and ...

Health scientists and drug industry executives around the world are on alert after the confirmation of Robert F. Kennedy Jr., who spreads antivaccine misinformation and has often derided the ...

Moderna is set to release its fourth-quarter earnings on Friday before the opening bell. Here's a look at what to expect in ...

Norovirus is highly infectious and causing a lot of illness this winter. Several vaccine candidates are making their way through clinical trials.

However, analysts project potential upside of 92% in 2025, according to the Street-high estimate.  Investors should also note that Merck pays a dividend yielding 3.71%, more than twice the healthcare ...

Janney Montgomery Scott LLC lowered its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 21.0% in the fourth quarter, ...

Equity markets performed well in January, as they often do, but as the dust settles on that early-year run, the strategy for ...

Star portfolio manager Cathie Wood’s Ark Investment Management filed its 13F holdings report for the fourth quarter on Feb. 4 ...

Explore the truth behind false claims that Moderna's CEO confessed to creating a COVID-19 vaccine before the pandemic, and the context of his remarks on vaccine production.